Merck beats estimates on fourth-quarter on earnings—but stock slides pre-market on tepid 2025 guidance
Merck (MRK) reported fourth quarter and full year earnings Tuesday, in line with Wall Street estimates. The bad news: Its stock was down more than 8% in pre-market trading, largely because of weaker than expected 2025 guidance.
Financial writer advises caution on investing in Merck & Co., Inc. due to negative sentiment and potential price declines.
Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of foreign exchange, ...
The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is ...
Citi analyst Geoff Meacham maintained a Buy rating on Merck & Company (MRK – Research Report) today and set a price target of $115.00. The ...
Financial writer recommends Merck & Co., Inc. as a strong healthcare stock despite recent challenges, citing strong potential ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
We recently published an article titled Jim Cramer’s Game Plan: 15 Stocks in Focus. In this article, we are going to take a ...
Merck on Tuesday missed earnings estimates, lowered its guidance for this year’s earnings, and withdrew a target for sales of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback